



4th Swedish Medicinal Chemistry Symposium

17-18 April, 2024. Organizer: Section for Medicinal Chemistry, Swedish Pharmaceutical Society

April 17	
09.15	Registration and coffee
09.45	Opening remarks – House keeping Chair: Lena Ripa, AstraZeneca
10.00	An IL-17A crystallization system supporting small molecule structure-based drug design Maria Håkansson, SARomics Biostructures
10.30	Application of SYN321 in Osteoarthritis Management. The Science behind the Local Injection Technology HYDRO-LINK Antonio Bermejo Gómez, Synartro
11.00	Mimicking nature's design – pseudoglucosinolates as prodrugs for bioresponsive isothiocyanate release Philipp Klahn, University of Gothenburg
11.30	Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells Stefan Svensson Gelius, Oncopeptides
12.00 – 13.30	Lunch
	Chair: Ulf Nilsson, Lund University
13.30	The FragMAX facility for structure-based drug discovery at MAX IV Laboratory Tobias Krojer, MAX IV Laboratory
14.00	"Scratching the surface" with skin PKPD Stefan Eirefelt, LEO Pharma
14.30	Is functionalization of C-H bonds interesting in medicinal chemistry? Magnus Johansson, AstraZeneca
15.00 – 15.45	Coffee break – Poster session
15.45	Targeting metabolic reprogramming in leukemia Karin Lindkvist, Lund University
16.15	Discovery and pre-clinical characterization of AZD4604, a potent and selective inhaled JAK1 inhibitor in clinical development Magnus Nilsson, AstraZeneca
16.45	Accelerating drug design with AI & simulation Eva Nittinger, AstraZeneca
17.15 – 19.00	Poster session – Refreshments



April 18	
08.45	House keeping Chair: Anders Karlén, Uppsala University
09.00	Award Läkemedelskemiska priset Anders Karlén, Uppsala University
09.15	Award lecture Läkemedelskemiska Priset To be announced.
10.00	Coffee break – Poster session
10.45	Short presentations selected from abstracts Substrate-Derived Sortase A Inhibitors: Targeting Antimicrobial Resistance Jordi Hintzen, University of Gothenburg
11.00	Design, Synthesis and Evaluation of novel macrocyclic peptidomimetics targeting the insulin- regulated aminopeptidase (IRAP) Esther Olaniran Håkansson, Uppsala University
11.15	Optimization of the N Piperidinyl Benzimidazolone Derivatives as Potent and Selective Inhibitors of 8 Oxo Guanine DNA Glycosylase 1 Zuzanna Szaruga, Karolinska Institutet, SciLifeLab
11.30	In vivo assembly of bioresorbable organic bioelectronics as a therapeutic modality Roger Olsson, Lund University
12.00 – 13.30	Lunch
	Chair: Peter Sjö, Drugs for Neglected Diseases initiative (DNDi)
13.30	Late Stage Chemical Process Development and Setting Efficient Control Strategies Hanna Cotton, Novo Nordisk
14.00	Development and Mechanism of the MTHFD1/2 Inhibitor TH9619 Martin Henriksson, One-Carbon Therapeutics
14.30	Coffee break
15.00	Modulating Gene Expression with Small Molecules Erik Chorell, Umeå University

Sponsors

15.45 – 16.00

15.30





Concluding remarks – End of Meeting

Poster award





